DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
VIDOFLUDIMUS
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Cholangitis, Sclerosing; Colitis, Ulcerative; Inflammatory Bowel Diseases; Multiple Sclerosis; Severe Acute Respiratory Syndrome
Dihydroorotate dehydrogenase inhibitor
VIDOFLUDIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
8Y1PJ3VG81
Molecule Type:
Small molecule
Molecular Formula:
C20H18FNO4
Molecular Weight:
355.37
AlogP:
4.0
PSA:
75.63
HBD:
2.0
HBA:
#RotB:
5.0
Source:
IMARADENANT
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Adenosine A2a receptor antagonist
IMARADENANT
×
Maximum Phase:
2
First Approval:
None
UNII:
770140J08A
Molecule Type:
Small molecule
Molecular Formula:
C15H11ClFN5
Molecular Weight:
315.74
AlogP:
3.28
PSA:
77.58
HBD:
1.0
HBA:
#RotB:
2.0
Source:
SPH-3127
2
Small molecule
Investigational
Unknown
Unknown
Hypertension
Unknown
SPH-3127
×
Maximum Phase:
2
First Approval:
None
UNII:
C2M78A9V6Z
Molecule Type:
Small molecule
Molecular Formula:
C22H32N6O4
Molecular Weight:
444.54
AlogP:
1.53
PSA:
110.61
HBD:
2.0
HBA:
#RotB:
8.0
Source:
IPI-549
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
IPI-549
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CALDARET MONOHYDRATE
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure; Myocardial Infarction
Unknown
CALDARET MONOHYDRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
2SH110E854
Molecule Type:
Small molecule
Molecular Formula:
C11H18N2O4S
Molecular Weight:
274.34
AlogP:
0.65
PSA:
69.64
HBD:
2.0
HBA:
#RotB:
2.0
Source:
PF-03635659
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Unknown
PF-03635659
×
Maximum Phase:
2
First Approval:
None
UNII:
O0RG3QM34H
Molecule Type:
Small molecule
Molecular Formula:
C28H32N2O3
Molecular Weight:
444.58
AlogP:
4.49
PSA:
75.79
HBD:
2.0
HBA:
#RotB:
9.0
Source:
ALFLUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
ALFLUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A49A7A5YN4
Molecule Type:
Small molecule
Molecular Formula:
C28H31F3N8O2
Molecular Weight:
568.6
AlogP:
4.84
PSA:
100.44
HBD:
2.0
HBA:
#RotB:
11.0
Source:
TEBANICLINE TOSYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Neuronal acetylcholine receptor; alpha4/beta2 agonist
TEBANICLINE TOSYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
CP1A26546Z
Molecule Type:
Small molecule
Molecular Formula:
C16H19ClN2O4S
Molecular Weight:
370.86
AlogP:
1.48
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
S-777469
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Cannabinoid CB2 receptor agonist
S-777469
×
Maximum Phase:
2
First Approval:
None
UNII:
88NI79737I
Molecule Type:
Small molecule
Molecular Formula:
C23H27FN2O4
Molecular Weight:
414.48
AlogP:
3.42
PSA:
88.4
HBD:
2.0
HBA:
#RotB:
6.0
Source:
NEVANIMIBE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Acyl coenzyme A:cholesterol acyltransferase 1 inhibitor
NEVANIMIBE
×
Maximum Phase:
2
First Approval:
None
UNII:
VK9OS8R205
Molecule Type:
Small molecule
Molecular Formula:
C27H39N3O
Molecular Weight:
421.63
AlogP:
6.63
PSA:
44.37
HBD:
2.0
HBA:
#RotB:
7.0
Source:
PERFLUORO TERT-BUTYLCYCLOHEXANE
2
Small molecule
Investigational
Unknown
Unknown
Brain Injuries
Unknown
PERFLUORO TERT-BUTYLCYCLOHEXANE
×
Maximum Phase:
2
First Approval:
None
UNII:
3ZX1Z33VUU
Molecule Type:
Small molecule
Molecular Formula:
C10F20
Molecular Weight:
500.07
AlogP:
6.56
PSA:
0.0
HBD:
0.0
HBA:
#RotB:
1.0
Source:
SELONSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hepatitis, Alcoholic; Hypertension, Pulmonary
Mitogen-activated protein kinase kinase kinase 5 inhibitor
SELONSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
NS3988A2TC
Molecule Type:
Small molecule
Molecular Formula:
C24H24FN7O
Molecular Weight:
445.5
AlogP:
4.68
PSA:
90.52
HBD:
1.0
HBA:
#RotB:
6.0
Source:
2-IMINOBIOTIN
2
Small molecule
Investigational
Unknown
Unknown
Hypoxia-Ischemia, Brain
Unknown
2-IMINOBIOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
HXH71NRQ5C
Molecule Type:
Small molecule
Molecular Formula:
C10H17N3O2S
Molecular Weight:
243.33
AlogP:
0.61
PSA:
85.21
HBD:
4.0
HBA:
#RotB:
5.0
Source:
X-82
2
Small molecule
Investigational
Unknown
Unknown
Adenocarcinoma; Neoplasms; Pancreatic Neoplasms; Macular Degeneration
Platelet-derived growth factor receptor inhibitor
X-82
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NEBOGLAMINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Glutamate [NMDA] receptor positive allosteric modulator
NEBOGLAMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
12EA34U5B8
Molecule Type:
Small molecule
Molecular Formula:
C13H24N2O3
Molecular Weight:
256.35
AlogP:
1.26
PSA:
92.42
HBD:
3.0
HBA:
#RotB:
5.0
Source:
TARLOXOTINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor inhibitor
TARLOXOTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
H8768UL06V
Molecule Type:
Small molecule
Molecular Formula:
C24H24BrClN9O3+
Molecular Weight:
601.87
AlogP:
4.6
PSA:
140.76
HBD:
2.0
HBA:
#RotB:
9.0
Source:
VAFIDEMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Borderline Personality Disorder
Unknown
VAFIDEMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
LZ82JLT4UP
Molecule Type:
Small molecule
Molecular Formula:
C19H20N4O2
Molecular Weight:
336.4
AlogP:
2.88
PSA:
86.2
HBD:
2.0
HBA:
#RotB:
7.0
Source:
PHORBOL MYRISTATE ACETATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Leukemia
Unknown
PHORBOL MYRISTATE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NI40JAQ945
Molecule Type:
Small molecule
Molecular Formula:
C36H56O8
Molecular Weight:
616.84
AlogP:
5.75
PSA:
130.36
HBD:
3.0
HBA:
#RotB:
15.0
Source:
ONO-2952
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Translocator protein antagonist
ONO-2952
×
Maximum Phase:
2
First Approval:
None
UNII:
ZH8CPX4YNB
Molecule Type:
Small molecule
Molecular Formula:
C22H20ClFN2O2
Molecular Weight:
398.87
AlogP:
4.95
PSA:
45.33
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PF-03715455
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Pulmonary Disease, Chronic Obstructive
MAP kinase p38 alpha inhibitor
PF-03715455
×
Maximum Phase:
2
First Approval:
None
UNII:
0TJ631J0KP
Molecule Type:
Small molecule
Molecular Formula:
C35H34ClN7O3S2
Molecular Weight:
700.29
AlogP:
7.8
PSA:
129.6
HBD:
4.0
HBA:
#RotB:
10.0
Source:
EMVODODSTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Neurofibromatosis 2
Unknown
EMVODODSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H20Cl2N2O3
Molecular Weight:
467.35
AlogP:
6.63
PSA:
54.56
HBD:
1.0
HBA:
#RotB:
3.0
Source:
CYTIDINE
2
Small molecule
Investigational
Unknown
Unknown
Bipolar Disorder
Unknown
CYTIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5CSZ8459RP
Molecule Type:
Small molecule
Molecular Formula:
C9H13N3O5
Molecular Weight:
243.22
AlogP:
-2.56
PSA:
130.83
HBD:
4.0
HBA:
#RotB:
2.0
Source:
GSK2838232
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Unknown
GSK2838232
×
Maximum Phase:
2
First Approval:
None
UNII:
G9C7884M8M
Molecule Type:
Small molecule
Molecular Formula:
C48H73ClN2O6
Molecular Weight:
809.57
AlogP:
9.46
PSA:
107.38
HBD:
2.0
HBA:
#RotB:
13.0
Source:
BERUBICIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Glioblastoma; Glioma
DNA topoisomerase II inhibitor
BERUBICIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
7BA3X03948
Molecule Type:
Small molecule
Molecular Formula:
C34H36ClNO11
Molecular Weight:
670.11
AlogP:
2.23
PSA:
195.07
HBD:
5.0
HBA:
#RotB:
8.0
Source:
HEME ARGINATE
2
Small molecule
Investigational
Unknown
Unknown
Myocardial Infarction; Acute Kidney Injury; Myocardial Ischemia; Porphyrias; Reperfusion Injury
Unknown
HEME ARGINATE
×
Maximum Phase:
2
First Approval:
None
UNII:
R1B526117P
Molecule Type:
Small molecule
Molecular Formula:
C40H48FeN8O6+2
Molecular Weight:
792.72
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RADEZOLID
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia
Bacterial 70S ribosome inhibitor
RADEZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
53PC6LO35W
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN6O3
Molecular Weight:
438.46
AlogP:
2.36
PSA:
112.24
HBD:
3.0
HBA:
#RotB:
8.0
Source:
GPI-1485
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
GPI-1485
×
Maximum Phase:
2
First Approval:
None
UNII:
0709BVY57W
Molecule Type:
Small molecule
Molecular Formula:
C12H19NO4
Molecular Weight:
241.29
AlogP:
1.07
PSA:
74.68
HBD:
1.0
HBA:
#RotB:
4.0
Source:
EXEPORFINIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Staphylococcal Infections
Unknown
EXEPORFINIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1912L54M2V
Molecule Type:
Small molecule
Molecular Formula:
C44H50Cl2N6O2
Molecular Weight:
765.83
AlogP:
8.94
PSA:
75.82
HBD:
2.0
HBA:
#RotB:
12.0
Source:
IBOGAINE
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Opioid-Related Disorders
Unknown
IBOGAINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3S814I130U
Molecule Type:
Small molecule
Molecular Formula:
C20H26N2O
Molecular Weight:
310.44
AlogP:
3.94
PSA:
28.26
HBD:
1.0
HBA:
#RotB:
2.0
Source:
BIMOSIAMOSE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis; Pulmonary Disease, Chronic Obstructive
Selectin inhibitor
BIMOSIAMOSE
×
Maximum Phase:
2
First Approval:
None
UNII:
97B5KCW80W
Molecule Type:
Small molecule
Molecular Formula:
C46H54O16
Molecular Weight:
862.92
AlogP:
1.98
PSA:
273.36
HBD:
10.0
HBA:
#RotB:
19.0
Source:
TETRAHYDROURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Central Nervous System Neoplasms; Head and Neck Neoplasms; Myelodysplastic Syndromes; Neoplasms; Carcinoma, Non-Small-Cell Lung
Unknown
TETRAHYDROURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0NIZ8H6OL8
Molecule Type:
Small molecule
Molecular Formula:
C9H16N2O6
Molecular Weight:
248.24
AlogP:
-2.84
PSA:
122.49
HBD:
5.0
HBA:
#RotB:
2.0
Source:
AZD4205
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell, Peripheral
Tyrosine-protein kinase JAK1 inhibitor
AZD4205
×
Maximum Phase:
2
First Approval:
None
UNII:
3BY9Z3M34G
Molecule Type:
Small molecule
Molecular Formula:
C25H31N9O2
Molecular Weight:
489.58
AlogP:
2.69
PSA:
116.23
HBD:
3.0
HBA:
#RotB:
7.0
Source:
ODELEPRAN
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism
Opioid receptors; mu/kappa/delta antagonist
ODELEPRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
4VZT670SD9
Molecule Type:
Small molecule
Molecular Formula:
C20H24FN3O3
Molecular Weight:
373.43
AlogP:
3.02
PSA:
86.47
HBD:
2.0
HBA:
#RotB:
8.0
Source:
POSELTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Tyrosine-protein kinase BTK inhibitor
POSELTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
D01E4B1U35
Molecule Type:
Small molecule
Molecular Formula:
C26H26N6O3
Molecular Weight:
470.53
AlogP:
4.64
PSA:
95.76
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NARONAPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 4 (5-HT4) receptor agonist
NARONAPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
058896B00B
Molecule Type:
Small molecule
Molecular Formula:
C27H41ClN4O5
Molecular Weight:
537.1
AlogP:
2.95
PSA:
106.36
HBD:
2.0
HBA:
#RotB:
11.0
Source:
1
2
…
110
111
112
113
114
115
116
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA